Latest first-line antihistamine for urticaria in Australia
Key things to know about bilastine
Sign up to MediScene
To access this content, please register or log in.
Experience the full suite of Mediscene features such as:
References
- Zuberbier T et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2021;00:1–33.
- Australasian Society of Clinical Immunology and Allergy. ASCIA Chronic Spontaneous Urticaria (CSU) Position Paper and Treatment Guidelines. Available from https://www.allergy.org.au/hp/papers/chronic-spontaneous-urticaria-csu-guidelines (accessed March 2023).
- O’Donnell BF et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197–201.
- Allertine (bilastine) Approved Product Information. May 2023.
- Australian Government Department of Health and Aged Care. Therapeutic Goods Administration: Notice of interim decisions on proposed amendments to the Poisons Standard – ACMS, ACCS and Joint ACMS–ACCS meetings, November 2020. Available from https://www.tga.gov.au/resources/publication/scheduling- decisions-interim/notice-interim-decisions-proposed-amendments-poisons-standard-acms-accs-and-joint- acms-accs-meetings-november-2020/22-bilastine (accessed March 2023).
- Zuberbier T et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65:516–28.
- Kawauchi H et al. Antihistamine for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci 2019;20(1):213.
- Yagami A et al. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol 2017;44(4):375–85.